Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Volumn 27, Issue 5, 2012, Pages 2023-2028

  González Espinoza, Liliana ^a   Rojas Campos, Enrique ^b   Medina Pérez, Miguel ^b   Peña Quintero, Patricia ^b   Gómez Navarro, Benjamin ^b   Cueto Manzano, Alfonso M ^b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PENTOXIFYLLINE; RENAL DIALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866534289     PISSN: None     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr579     Document Type: Article

References (0)